Severe colitis after administration of UFT chemotherapy for temporal bone carcinoma

Expert Opinion on Drug Safety

Volumn 3, Issue 2, 2004, Pages 89-92

  Akay, Sinan ^a   Ozutemiz O ^a   Doganavsargil, B ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Colitis; Dihydropyrimidine dehydrogenase (DPD) deficiency; Gastrointestinal (GI) side effects; UFT

Indexed keywords

AMIKACIN; ANTINEOPLASTIC AGENT; CILASTATIN; CIPROFLOXACIN; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; LOPERAMIDE; METRONIDAZOLE; TEGAFUR; TROPISETRON; UFT; URACIL; UFT(R) DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; BONE CANCER; CASE REPORT; CLINICAL TRIAL; COLITIS; COLON MUCOSA; COLONOSCOPY; DIARRHEA; DISEASE SEVERITY; DRUG METABOLISM; DRUG TISSUE LEVEL; EXON; EXUDATE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GRANULOCYTOPENIA; HEMATOCHEZIA; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PETECHIA; PHYSICAL EXAMINATION; SQUAMOUS CELL CARCINOMA; STOMATITIS; VOMITING; COLON DISEASE; DRUG COMBINATION; MIDDLE AGED; SKULL TUMOR; TEMPORAL BONE;

ANTINEOPLASTIC AGENTS; COLONIC DISEASES; COLONOSCOPY; DRUG COMBINATIONS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; SKULL NEOPLASMS; TEGAFUR; TEMPORAL BONE; URACIL;

EID: 2342656385     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.2.89     Document Type: Article

References (18)

1. MAEHARA Y, KAKEJI Y, OHNO S, RABA H, SUGIMACHI K: Scientific basis for the combination of tegafur with uracil. Oncology (Huntingr.) (1997) 11(9 Suppl. 10): 14-21.
2. NAKAJIMA O, IHARA K, ISODA T et al.: Phase I and II studies on mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Jpn. J. Cancer Chemother. (1980) 7:1558-1568.
3. TREVISANI F, SIMONCINI M, ALAMPI G, BERNARDI M: Colitis associated with chemotherapy with 5-fluorouracil. Hepatogastroenterelogy (1997) 44(15):710-712.
4. BAKER JL, GOSLAND MP, HERRINGTON JD, RECORD KE: Cytomegalovirus colitis after 5-fluorouracil and interferon α therapy. Pharmacotherapy (1994) 14(2):246-249.
5. MADISCH A, WIEDBRAUCK F, MARQUAD F, STOLTE M, HOTZ J: 5-fluorouracil-induced colitis - a review based upon consideration of six cases. Z. Gastroenterol. (2002) 40(2):59-66.
6. MANI S, SCIORTINO D, SAMUELS B et al.: Phase II trial of uracil/tegafur plus leucovarin in patients with advanced biliary carcinoma. Invest. New Drugs (1999) 17:97-101.
7. PAZDUR R, LASSERE Y, DIAZ-CANTON E et al.: A Phase I and pharmacokinetic study of oral uracil, ftorafur and leucovarin in patients with advanced cancer. Cancer Chemother. Pharmacol. (1996) 37(6):581-586.
8. PAZDUR R, LASSERE Y, DIAZ-CANTON E, BRADY B, HO DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovarin: 14-day schedule. Invest. New Drugs (1997) 15(2):123-128.
9. PAZDUR R, LASSERE Y, DIAZ-CANTON E, HO DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovarin: 28-day schedule. Cancer Invest. (1998) 16(3):145-151.
10. DE BONO JS, TWELVES CJ: The oral fluorinated pyrimidines. Invest. New Drugs (2001) 19:41-59.
11. HARRIS BE, CARPENTER JE, DIASIO RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer (1991) 68(3):499-501.
12. RIDGE SA, SLUDDEN J, WEI X et al.: Dibydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br. J. Cancer (1998) 77:497-500.
13. WEI X, MCLEOD HL, MCMURROUGH J, GONZALEZ FJ, FERNANDEZ-SALGUERO P: Molecular basis of human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. (1996) 98:610-615.
14. RIDGE SA, SLUDDEN J, BROWN O et al.: Dihydropyrimidine dehydrogenase pharmacokinetics in Caucasian subjects. Br. J. Clin. Pharmacol. (1998) 46:610-615.
15. KRONAWITTER U, KEMENY NE, BLUMGART L: Neutropenic enterocolitis in a patient with colorectal carcinoma. Cancer (1997) 80(4):656-660.
16. IVENSON TJ, CHAN A. Pseudomembranous colitis complicating chemotherapy. Lancet (1992) 339(8786):192-193.
17. VAN DEN BRANDE J, SCHRIJVERS D, COLPAERT C, VERMORKEN JB: Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. Pharmacotherapy (1994) 14(2):246-249.
18. HASKELL CM: Drugs used in cancer chemotherapy. In: Cancer treatment. Haskell CM (Ed.), WB Saunders Company, Philadelphia (1990):44-102.